mesoblast; (asx: msb; nasdaq:meso) is a world leader in innovative cell-based medicines. we have leveraged our proprietary technology platforms based on specialized cells known as mesenchymal lineage adult stem cells (mlcs) to establish what we believe is the most advanced cellular medicines portfolio in the industry. our ‘off-the-shelf’ products are allogeneic - meaning cells from one donor may be used in many different recipients without the need for matching. our licensee in japan has launched its mlc-based product for acute graft versus host disease in children and adults in japan. it is the first allogeneic cell-based product in japan to be fully approved in japan. we believe we are well positioned to have the first industrially manufactured allogeneic cell-based product approved in the united states. our lead product candidates under investigation are: • mpc-150-im for chronic heart failure • mpc-06-id for chronic low back pain due to disc degeneration • msc-100-iv for acute graf
Company profile
Ticker
MESO, MEOBF
Exchange
Website
CEO
Silviu Itescu
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
MESO stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
16 Apr 24
6-K
Current report (foreign)
16 Apr 24
6-K
Current report (foreign)
16 Apr 24
6-K
Current report (foreign)
16 Apr 24
F-3
Shelf registration (foreign)
16 Apr 24
6-K
Current report (foreign)
26 Mar 24
6-K
Current report (foreign)
20 Mar 24
6-K
Current report (foreign)
14 Mar 24
6-K
Current report (foreign)
11 Mar 24
6-K
Current report (foreign)
29 Feb 24
Latest ownership filings
SC 13G/A
George Gregory
9 Apr 24
SC 13G/A
George Gregory
3 Apr 24
SC 13G/A
George Gregory
20 Mar 24
SC 13G/A
M&G INVESTMENT MANAGEMENT LTD
6 Sep 23
SC 13G/A
George Gregory
6 Sep 23
SC 13G
George Gregory
10 May 23
SC 13G/A
M&G INVESTMENT MANAGEMENT LTD
20 Jan 23
SC 13G/A
M&G INVESTMENT MANAGEMENT LTD
6 Sep 22
SC 13G/A
M&G INVESTMENT MANAGEMENT LTD
8 Apr 22
SC 13G/A
M&G Alternatives Investment Management Ltd
19 Jan 22
Financial summary
Quarter (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
29.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 44 |
Opened positions | 8 |
Closed positions | 8 |
Increased positions | 18 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 6.81 bn |
Total shares | 34.08 mm |
Total puts | 44.20 k |
Total calls | 412.10 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
George Gregory | 32.28 mm | $96.69 mm |
Penbrook Management | 255.65 k | $999.59 mm |
Group One Trading | 250.35 k | $978.87 mm |
MS Morgan Stanley | 214.68 k | $839.41 mm |
BLK Blackrock | 140.72 k | $550.20 mm |
Jane Street | 109.27 k | $413.06 mm |
Lazari Capital Management | 86.03 k | $336.39 mm |
Millennium Management | 83.20 k | $325.31 mm |
Susquehanna International | 79.12 k | $309.35 mm |
Simplex Trading | 74.24 k | $290.00 k |
News
United Airlines Reports Upbeat Results, Joins Children's Place, Interactive Brokers And Other Big Stocks Moving Higher On Wednesday
17 Apr 24
Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session
8 Apr 24
Model N, Ducommun, Perpetua Resources And Other Big Stocks Moving Higher On Monday
8 Apr 24
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
3 Apr 24
Why Cal-Maine Foods Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
3 Apr 24
Press releases
Reddit Inc. (NYSE: RDDT) Surges, Uncovering Undervalued Opportunities: DYAI, INBS, MESO, VTAK
28 Mar 24
FDA Commentary Sends Biotech Soaring During Premarket Hours
26 Mar 24
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
25 Mar 24
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
13 Mar 24
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
10 Mar 24